Devyser Diagnostics AB (publ) (DVYSR) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Divisor Diagnostics Q2 Report 2026 presentation. During the Q&A session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now, I will hand the conference over to the speakers. CEO Jan Wallstrom and CFO Sabina Berlin, please go ahead. Good morning and welcome to Devizor's Q2 2026 earnings call. I'm Jan Wallström, CEO of Devizor and would like to thank you everyone for joining our call today. On the call today we have in addition to myself also our CFO Sabina Berlin. I will start with a short summary of highlights for the quarter before handing over to Sabina for a more detailed review of our financial results. for April to June and then we'll go through an update on our recent commercial activities. Second quarter had a setback in sales due to lower than expected sales to our biggest distributor. However, despite this, we had positive EBIT earning for the fifth consecutive quarter and for the first half year improved profitability when we had flat sales. In the second quarter of the year, we had weak sales in transplant products, as I said, as lab onboarding has taken more time and the volume buildup is therefore delayed. The underlying growth the last year has been really good and we are positive to see a strong growth in 2027. Underlying gross margin was in line with our target of 80%. The reason for the lower margin in the quarter is inventory effects. We made profit on EBIT this quarter too, showing that we control our costs in a good way and can deliver positive results. We, as we communicated before, finalized the Cybergene acquisition April 1. In the quarter, we signed Niklas Axelsson as new CFO and he will start in the third quarter. We also won a tender in Italy, an existing customer, where the volumes increa...